Xonvea will be prescribed to women who are sick during pregnancy where conservative treatment has failed
(LON:APH) has confirmed its morning sickness treatment Xonvea has received marketing approval in Ireland.
This paves the way for the first launch of the product outside the UK. The company to start selling the drug in the Republic in the final quarter of this year.
As in the UK, it will be prescribed for nausea and vomiting in pregnancy where conservative management has failed.
The condition affects 70-80% of women during pregnancy in Ireland, mirroring what is seen in Britain.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Alliance Pharma PLC named herein, including the promotion by the Company of Alliance Pharma PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE